CEA [CHINA EASTERN AIRLINESRP] 6-K: (Original Filing)

[China Eastern Airlinesrporation Limitedte June 3, 2013 By Wang Jian For Main Board and GEM listed issuers Monthly Return of Equity Issuer on Movements in Securities For the month ended (dd/mm/yyyy) : 2013 31/05/ To : Hong Kong Exchanges and Clearing Limited Name of Issuer China Eastern Airlinesrporation Limited (thempany)]

By | 2016-02-04T11:04:33+00:00 June 3rd, 2013|Categories: CEA, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

THTI [THT Heat Transfer Technology] DEF 14A: (Original Filing)

[SCHEDULE 14A (RULE 14a-101) Check the appropriate box: [ ] Preliminary Proxy Statement [ ] [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] THT HEAT TRANSFER TECHNOLOGY, INC. _______________________________________________________________ Payment of Filing Fee (Check the appropriate box): [X] No fee required. [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title]

CEA [CHINA EASTERN AIRLINESRP] 6-K: China Eastern Airlinesrporation Limitedte June 3, 2013 By

[China Eastern Airlinesrporation Limitedte June 3, 2013 By Wang Jian For Main Board and GEM listed issuers Monthly Return of Equity Issuer on Movements in Securities For the month ended (dd/mm/yyyy) : 2013 31/05/ To : Hong Kong Exchanges and Clearing Limited Name of Issuer China Eastern Airlinesrporation Limited (thempany)]

By | 2016-02-04T11:05:27+00:00 June 3rd, 2013|Categories: CEA, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

THTI [THT Heat Transfer Technology] DEF 14A: SCHEDULE 14A (RULE 14a-101) Check the appropriate box:

[SCHEDULE 14A (RULE 14a-101) Check the appropriate box: [ ] Preliminary Proxy Statement [ ] [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] THT HEAT TRANSFER TECHNOLOGY, INC. _______________________________________________________________ Payment of Filing Fee (Check the appropriate box): [X] No fee required. [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title]

HIMX [Himax Technologies] F-3: (Original Filing)

[FORM F-3 REGISTRATION STATEMENT HIMAX TECHNOLOGIES, INC. Not Applicable Cayman Islands Not Applicable No. 26, Zih Lian Road, Puglisi & Associates (Name, address, and telephone number of agent for service) Copy to: James C. Lin, Esq. Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement, as determined] [3 June, 2013 Matter No.:878160 Doc. Re: 3182656v8 (852) 2842 9531 anna.chong@conyersdill.com Himax Technologies, Inc. No. 26, Zih Lian Road Sinshih District Tainan City 74148 Taiwan Dear Sirs, Himax Technologies, Inc. (the “Company”) Re : Commission Securities Act Registration Statement Ordinary Shares New Shares Innolux Sale Shares For the purposes of giving this opinion, we have examined and relied upon] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Board of Directors Himax Technologies, Inc. We consent to the use of our reports with respect to the consolidated financial statements and the effectiveness of internal control over financial reporting incorporated by reference herein and to the reference to our firm under the heading “Experts” in the prospectus. Taipei, Taiwan (the Republic]

By | 2016-03-23T11:30:39+00:00 June 3rd, 2013|Categories: Chinese Stocks, HIMX, SEC Original|Tags: , , , , , |0 Comments

HIMX [Himax Technologies] F-3: FORM F-3 REGISTRATION STATEMENT HIMAX TECHNOLOGIES, INC. Not

[FORM F-3 REGISTRATION STATEMENT HIMAX TECHNOLOGIES, INC. Not Applicable Cayman Islands Not Applicable No. 26, Zih Lian Road, Puglisi & Associates (Name, address, and telephone number of agent for service) Copy to: James C. Lin, Esq. Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement, as determined] [3 June, 2013 Matter No.:878160 Doc. Re: 3182656v8 (852) 2842 9531 anna.chong@conyersdill.com Himax Technologies, Inc. No. 26, Zih Lian Road Sinshih District Tainan City 74148 Taiwan Dear Sirs, Himax Technologies, Inc. (the “Company”) Re : Commission Securities Act Registration Statement Ordinary Shares New Shares Innolux Sale Shares For the purposes of giving this opinion, we have examined and relied upon] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Board of Directors Himax Technologies, Inc. We consent to the use of our reports with respect to the consolidated financial statements and the effectiveness of internal control over financial reporting incorporated by reference herein and to the reference to our firm under the heading “Experts” in the prospectus. Taipei, Taiwan (the Republic]

By | 2016-03-23T11:32:01+00:00 June 3rd, 2013|Categories: Chinese Stocks, HIMX, Webplus ver|Tags: , , , , , |0 Comments

SMI [SEMICONDUCTOR MANUFACTURING INTERNATIONAL] 6-K: (Original Filing)

[SEMICONDUCTOR MANUFACTURING INTERNATIONAL CORPORATION (Incorporated in the Cayman Islands with limited liability) (STOCK CODE: 981) ESTABLISHMENT OF A JOINT VENTURE IN BEIJING, THE PRC ESTABLISHMENT OF THE JOINT VENTURE The Company is pleased to announce that, on 3 June 2013, the Company entered into the Joint Venture Agreement with SMIC Beijing, BIDIMC and ZDG in relation to the establishment of]

By | 2016-03-08T15:36:43+00:00 June 3rd, 2013|Categories: Chinese Stocks, SEC Original, SMI|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited First Quarter 2013 Financial Results -Conference call scheduled for Tuesday, May 28, 2013 at 8:00 AM EDT - BEIJING, May 28, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2013. First Quarter 2013 Financial Highlights (Year-over-year] [Sinovac Files New Drug Application for EV71 Vaccine and Receives Filing Acceptance from Beijing Drug Administration BEIJING, May 30, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced Sinovac's new drug application (NDA) for its proprietary EV71 vaccine has been filed and accepted by the Beijing Drug Administration. In terms of next] [Sinovac Appoints New Chief Financial Officer Vice President of Sinovac Named CFO BEIJING, May 31, 2013 /PRNewswire/ — Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that Ms. Nan Wang, Vice President of Sinovac, has been appointed as Chief Financial Officer, effective June 1, 2013. Mr. Danny Chung, who was Chief Financial Officer, has] []

By | 2016-03-24T00:20:20+00:00 June 3rd, 2013|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Skip to toolbar